Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Deferoxamine - DESFERAL injection
Product / population
DESFERAL injection in its labeled iron-intoxication/iron-overload context; not a newly constructed aluminum-overload dialysis regimen.
Renal method
Qualitative renal impairment; severe renal disease/anuria
Source revision
9/2022
Retrieved
2026-09-10
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Qualitative low-end dosing does not override severe-renal contraindication
The selected sources contraindicate severe renal disease/anuria but also advise low-end dosing in renal impairment. Dialyzability is described in overdose management.
What to reconcile: Do not invent a numerical severity boundary or a dialysis supplement. Specialist off-label aluminum regimens are not adjudicated here.
Novartis Pharmaceuticals Corporation / manufacturer prescribing information · DESFERAL injection in its labeled iron-intoxication/iron-overload context; not a newly constructed aluminum-overload dialysis regimen.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding
Do not invent a numerical renal threshold or dialysis supplement from qualitative restriction and removal information.
Dialysis evidence: Removal information only - not a dialysis regimen
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
The manufacturer label contraindicates severe renal disease or anuria and advises low-end dose selection in renal impairment without providing a clearance ladder. Monitor renal function for creatinine elevation, acute renal failure and tubular disorders. Its overdose section describes ready dialyzability; that observation is not a labeled routine dialysis replacement regimen. The retrieved document prints a September 2022 revision. These selected restrictions do not establish present product availability or adjudicate specialist off-label aluminum treatment.
Selected named sections only; not a complete monograph or independent clinical approval.
Selected exact-product labeling sections read. Original-source bytes and complete revision histories were not retained or reconciled; retrieval does not establish current product availability.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.